Since Th2 immune cells play an essential role in developing and maintaining AD, drugs targeting Th2 immune response, such as IL-4, IL-13, TSLP, and JAK/STAT small molecules, have become an important strategy for developing new treatments for AD. This evidence concerns the gene SOAT1 and Alzheimer disease.